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Abstract
The thermodynamic aspects of the polymorphic phase transition from α-indomethacin to
γ-indomethacin are the fundamental key to find the most bioavailable phase of indomethacin. In the
present work, varying the temperature and solvent permittivity changes the polymorphic transitions.
Hence, the thermodynamic properties such as enthalpy, Gibbs free energy, and entropy of both
indomethacin polymorphs are determined in terms of the solvent permittivity as functions of
indomethacin's temperature in a vacuum, which are crucially related to the stability, spontaneity, and
reversibility of the polymorphic transformation.
Keywords: bioavailability, DFT methods (B3LYP/3-21G/PCM), indomethacin, indomethacin
polymorphs, phase transition, thermodynamic functions.
INTRODUCTION
A drug can crystallize into different polymorphs, which are characterized by their unique spatial
arrangement with distinct physicochemical properties, in particular, different solubilities,
bioavailabilities and degrees of toxicity [1]. Furthermore, one crystalline arrangement can be
transformed into another by the so-called polymorphic phase transition [2]. The understanding on how
to induce or suppress polymorphic phase transitions plays a valuable role in the pharmaceutical
industry concerning the bioavailability and patentability of the medicine development process [1,
3-5].
2Notably, indomethacin (C19H16CINO4) is a very common drug mainly prescribed for its
analgesic, anti-inflammatory and antipyretic properties; however, at least seven unique crystalline
forms are known. Among them, the α- and γ-indomethacin polymorphs present high stability and
allow a crystallographic description, while all of the remaining polymorphs of indomethacin are
metastable [6,7]. Here, the thermodynamic properties of indomethacin were investigated in order to
find a phase transition driven by the permittivity of the medium [2], provided that a continuous
variation in a binary mixture produces a continuous variation in its permittivity value, as expressed in
equation (1) [2,8]. The permittivity εm in a binary system composed of two solvents, 1 and 2, whose
permittivities are ε1 and ε2, respectively, can be expressed as follows:
ln εm= a1 ln ε1+a2 ln ε2+a1a2 [K0+K1(a1-a2)+K(a1-a2)2] (1)
where a1 and a2 are the volumetric fractions of solvents 1 and 2 and Ki represent experimental
constants [8,9]. The permittivity is independent of the system size and therefore an intensive
thermodynamic parameter [10,11].
The importance of this study resides in the fact that, in general, crystals belonging to the same
spatial group have similar physical properties [12,13]. The α- and γ-indomethacin polymorphs belong
to the space groups P21 and P-1 respectively, which in turn are among the five most common space
groups of organic compounds from the Cambridge Crystallographic Data Centre (CCDC). If more
than one formula in the asymmetric unit is considered in the space groups (by asymmetric unit, a unit
cell composed of more than one chemical compound or molecule, for example, indomethacin and
ethanol exist in a single unit cell), then the five most common space groups are the following: P21/c
(27.8%), P-1 (23.5%), P21 (13.8%), P1 (8.5%) and P212121 (7.8%). On the other hand, if all of the
compounds of the CCDC are considered, the following most common space groups are obtained:
P21/c (36.6%), P1 (16.9%), P212121 (11.0%), C2/c (7.0%) and P21 (6.4%). Therefore, the generality of
the present study is justified by investigating the α- and γ-indomethacin polymorphic phase transition.
Accordingly, ab initio quantum methods (density functional theory, DFT, methods) could be used to
simulate the polymorphic phase transition between α- and γ-indomethacin, which is induced by a
range of distinct permittivity values for solvents at a fixed temperature of 298.15 K [6,7]. This range
3can be precisely controlled by considering the different proportions of solvents in a binary mixture as
expressed in equation (1) [8,14]. Hence, the change in the composition of the drug delivery vehicle
changes its permittivity, whereas the permittivity and pH values can be related [15,16], and thus,
several polymorphs of indomethacin can be experimentally synthesized by altering the pH of the
solvent [6], allowing a proper polymorphic transition analysis.
The goal of the present work is to characterize the phase transition of the α- and γ-polymorphs of
indomethacin and to establish its thermodynamic properties such as enthalpy, Gibbs free energy and
entropy by varying both the temperature and solvent permittivity in DFT computations, which are
related to the stability, spontaneity, reversibility and bioavailability of the polymorphs and their
transformation.
METHODOLOGY
The Gaussian09 program was initially used to determine standard thermodynamic quantities in a
vacuum such as the enthalpy (H), Gibbs free energy (G) and entropy (S), which are functions for the
α- and γ-indomethacin phases in solvents with different dielectric constant values at a fixed
temperature of 298.15 K for validation of the method. The computation was performed by DFT with
the B3LYP functional using the 3-21G basis set via the polarizable continuum model (PCM) [17-20],
using the integral equation formalism variant (IEFPCM) in the default self-consistent reaction field
(SCRF) computation. To preserve the number of indomethacin molecules, the original formation of
the α-structure inside the solvent consists of the nucleation of six molecules of indomethacin per unit
cell, while the nucleation of the γ-structure inside the solvent demands three indomethacin molecules
per unit cell [21].
Denoting extensive parameters by E1, E2, ...,En and intensive parameters by I1, I2, ..., In, a phase
transition can be defined by a discontinuity in the derivative of thermodynamic functions (denoted by
P) in terms of an intensive parameter Ii [22]. In this way, a n-order phase transition dependent on Ei is
characterized by a discontinuity in the transition point at the (n-1)-th derivative of the function P(Ei
(Ii),Ii), in which Ei is an extensive thermodynamic parameter that depends on the intensive parameters
4Ii: pressure [23,24], temperature, voltage [25], laser frequency [26], electric field [25], pressure
[27,28], permittivity [11] and so forth. The differential form of the thermodynamic function P(Ei (Ii),Ii)
can be expressed as dP = I1 dE1+ I2 dE2+ ...+In dEn [29]. For the present case, the Gibbs free energy is
G=μN+D2/(8πε), and its differential is given straightforwardly by dG=μdN+DdD/4πε. Therefore,
quantities such as the spontaneity, stability and reversibility of a phase transition can be interpreted by
means of G(Ei (Ii), Ii), H(Ei (Ii), Ii) and S(Ei (Ii), Ii), respectively [14,30]. As a particular case, a
first-order transition is a discontinuity in the function P(Ei (Ii), Ii) [22]. Therefore, the α to γ structural
transition can be described as a first-order phase transition in the entropy as a function of the
permittivity, as will be shown.
Table 1: Characterization of the unit cell of indomethacin polymorphs by the size of its edges (in Å) and angles.
1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid (C14H9ClO3)
Polymorph
Space
Group
unit cell edge unit cell angle
a b c α β γ
α-indomethacin P21 (4) 5.4616(16) 25.310(9) 18.152(7) 90° 94.38(3)° 90°
γ-indomethacin P1 (2) 9.236(5) 9.620(5) 10.887(5) 69.897(5)° 87.328(5)° 69.501(5)°
RESULTS AND DISCUSSION
Parameters such as the temperature, solvent permittivity, and pressure in the organic crystal or
pH of the medium can significantly modify the stability, solubility and bioavailability of drugs [31,32].
In an effort to improve drug bioavailability knowledge, the solvent permittivity was chosen as the
order parameter for thermodynamic analysis. The standard temperature for the polymorphic phase
transition between the α and γ phases of indomethacin in the vacuum was reached by the
computational method presented in the previous section. The main standard thermodynamic functions,
namely, H(D; ε, P0, T0, N), G(D; ε, P0, T0, N) and S(D; ε, P0, T0, N), were computed for six molecules
of indomethacin (N=6) in terms of the solvent permittivity ε at T0=298.15 K and P0=1 atm.
5Theoretical strategy validation: analysis of the enthalpy and Gibbs free energy in a first-order
phase transition
The protocol of the theoretical strategy can be summarized in the correspondence between the
simulated temperature for the structural phase transition from the α- to γ-indomethacin polymorphs
and the current literature, which are reported in Figure 1.
Figure 1: Enthalpy and Gibbs free energy. Comparative enthalpy and Gibbs free energy plots for α- and
γ-indomethacin.
In Figure 1, the enthalpy for both phases of indomethacin increases with the temperature at a
constant rate outside the phase equilibrium, while the Gibbs energy decreases, as expected from the
enthalpy expression H=G+TS [29,33].
The critical transition region is highlighted in the direction of the lower Gibbs free energy due to
the intersection between both Gibbs free energy curves, characterizing the phase balance, which is
corroborated by the current literature, in which the stable phase of γ-indomethacin is achieved at 120
K as well [34,35]. The discontinuity in the Gibbs free energy lies in a temperature range of 793.15 K
to 803.15 K due to the presence of a peak for γ-indomethacin.
6Standard thermodynamic parameters as a function of the solvent dielectric constant
The enthalpy and the Gibbs free energy are plotted in Figure 2 for both indomethacin
polymorphs, and their nonlinear behaviors were fitted by the Levenberg Marquardt method, in which
all of the coefficients of determination have a correlation given by R2 = 0.999, in such a way that the
quantities H(D; ε, P0, T0, N), G(D; ε, P0, T0, N) and S(D; ε, P0, T0, N), where S= (H-G)/T, are all
expressed in terms of the permittivity ε. Consequently, the theoretical predictions for some
transformation properties, such as spontaneity, stability and reversibility, are provided from the
standard expressions for Gibbs free energy, enthalpy, and entropy, respectively [30,14].
Figure 2: Enthalpy and Gibbs free energy for different solvents. Comparative enthalpy and Gibbs free
energy plots for α- and γ-indomethacin as a function of the solvent permittivity.
The curves shown in Figure 2 are fitted by the Levenberg Marquardt method 



a
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P , in which a,
b and c are constants to be determined. The Gibbs free energy and enthalpy of γ-indomethacin are
smaller than those of α-indomethacin for all permittivity values. Therefore, due to this finding as well
as its high degree of symmetry, the γ-structure is the most stable and therefore the least bioavailable
polymorph of indomethacin [36]. The negative difference between the Gibbs free energies guarantees
7the spontaneity of the structural transformation from α-indomethacin to γ-indomethacin [9,35]. The
parameters obtained from the fitting protocol are expressed in Table 2.
Table 2: Parameters from the fitting of the thermodynamic functions
Model Rational2
Equation P = (b + cε)/(a + ε)
Plot
Enthalpy of
ɑ-indomethacin
Gibbs free
energy of
ɑ-indomethacin
Enthalpy of
γ-indomethacin
Gibbs free energy of
γ-indomethacin
a 0.96476 ± 0.03971
0.99296 ±
0.0406
0.95438 ± 0.04712 0.71399 ± 0.07125
b 233.74839 ± 1.93428
-355.71274 ±
24.44109
-1765.40557 ±
101.89131
-1684.46834 ± 196.6459
c -233.83429 ± 0.57742
-833.15349 ±
0.59384
-2451.09728 ±
0.8954
-3043.42136 ± 1.38329
Reduced
Chi-Sqr
0.90922 0.95559 2.19566 5.52557
R-Square
(COD)
0.99985 0.99985 0.99974 0.99931
Adj.
R-Square
0.99981 0.9998 0.99967 0.99914
Finally, the values for the enthalpy and Gibbs free energy for α- and γ-indomethacin are given
by the following equations:
Hα = (-233.83429ε +233.74839)/(ε+0.96476)=-233.834 + 459.342/(0.96476 + ε) (2)
Hγ=-(2451.09728ε +1765.40557)/(ε+0.95438)=-2451.1 + 573.873/(0.95438 + ε) (3)
Gα=-(833.15349ε +355.71274)/(ε+0.99296)=-833.153 + 471.575/(0.99296 + ε) (4)
Gγ=(-3043.42136ε -1684.46834)/(ε+0.71399)=-3043.42 + 488.504/(0.71399 + ε) (5)
The sign of enthalpy variation (ΔH) between α- and γ-indomethacin characterizes an
endothermic (positive) or exothermic (negative) polymorphic transformation. Hence, from equations
(2) and (3), the polymorphic transformation from α-indomethacin to γ-indomethacin is observed to be
exothermic for all positive values of the permittivity. As an exceptional case, there is no heat
8exchange if Hα=Hγ. The transformation is endothermic if the relative permittivity assumes negative
values, which is the case of metamaterials [37-41]. In nanotechnology, negative permittivity values
are found in polyaniline–metal oxide (carbon nanotube) composites and in poly(vinylidene
fluoride)/Ni [(CH2CF2)n/Ni] chain composite films [37]. Mechanisms of formation of negative
dielectric properties, which can be applied to drug encapsulation, are also present in the literature [38
- 41].
The polar solvents employed in the energy computation SCRF=PCM are depicted, and the
respective permittivity value of each solvent is shown in parentheses: 1-bromooctane (5.0244), aniline
(6.8882), pentanal (10.0), 1-pentanol (15.13), 1-propanol (20.524), ethanol (24.852), 1-benzonitrile
(25.592), methanol (32.613), acetonitrile (35.688), 1,2-ethanediol (40.245), and water (78.3553).
The spontaneity of the phase transformation can be determined as a function of the Gibbs free
energy variation, as described by Figure 3 [29,33].
Figure 3: Gibbs free energy function versus the relative permittivity at the B3LYP/3-21G/PCM level.
A polymorphic transformation is spontaneous if ΔG < 0 [9], which also gives the direction of
transition from α → γ, i.e., establishing that the transformation from α- to γ-indomethacin is
spontaneous for all positive values of the permittivity. The transformation reaches equilibrium if ΔG
is close to zero, and according to Figure 3, this equilibrium state is reached if the relative permittivity
9is close to 1 [29,33]. In addition, for some negative values of permittivity, the transformation is
reversed, meaning that the transition for the more bioavailable polymorph is favorable [37].
Influence of the Entropy
The last thermodynamic function analyzed is the entropy, which provides information about the
reversibility of the polymorphic transformation and measures the degree of disorder of the
corresponding compound, whose values for both indomethacin forms are computed based on the
enthalpy H(D;ε,P0,T0,N) and Gibbs free energy G(D;ε,P0,T0,N) by means of the standard expression
S(D;ε,P0,T0,N) = (H G)/T, as outlined in Figure 4. From the second thermodynamic law, the
transformation is reversible only if ΔS=0; otherwise, the process is irreversible. Moreover, the entropy
of the whole system always increases [29,42]. Hence, the decrease in the entropy of indomethacin
results in an increase in the entropy of the solvent counterpart. The change in the sign of ΔS emerges
by means of a discontinuity and occurs at ε ≈ 11.46.
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Figure 4: Entropy versus relative permittivity at the B3LYP/3-21G/PCM level.
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This discontinuity in the entropy characterizes a phase transition driven by the permittivity of the
solvent [8]. Moreover, as seen from equation (6), there is also a discontinuity in the first derivative of
the entropy:
(6)
In addition, the standard relationship between the enthalpy and entropy variations, ΔG=ΔH-TΔS,
which can also be visualized in Figure 1, is constant [43], revealing that a phase transition occurs
spontaneously for all temperatures in the solvent with a dielectric constant below ε≈11.5. On the other
hand, if the same conditions were considered for solvents with a dielectric constant above ε≈11.5, a
very high temperature allows a spontaneous transformation in the opposite direction, from
γ-indomethacin to α-indomethacin. In fact, spontaneous transformation can also be achieved by
microwave excitation of the hydrogen bonds between molecules, which would be broken, inducing a
phase transition [8].
Permittivity is the order parameter that dominates the polymorphic transformations, although
pressure should be considered as well. In this case, crystallization occurs at high pressure, and new
polymorphs may arise with a higher degree of symmetry and hence less disorder [44]. From another
point of view, the same process occurs if the temperature is decreased [45]. Note that γ-indomethacin
is in the space group P-1, thus having a higher degree of symmetry than the α-structure and the
smallest disorder as a result [44]. Therefore, γ-indomethacin is produced from α-indomethacin if the
pressure increases through dry milling [9,10,45]. For this reason, it is speculated that under
high-pressure, γ-indomethacin immersed in solvents whose relative permittivity is greater than 12
transforms into α-indomethacin [9,44]. Note that the reversibility aspect of the transformation comes
from the difference in the entropy ΔS=Sγ-Sα. The entropy of indomethacin decreases in the
polymorphic transformation from α- to γ-indomethacin for relative permittivity values greater than
11.46.
Effect of the solvent permittivity on the solvation Gibbs free energy
The cycle of the solvation process can be evaluated from Diagram 1.
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ΔGVacuum
α-Indomethacin γ-Indomethacin
ΔGSolv1 ΔG’Solv1
ΔG1
α-Indomethacin γ-Indomethacin
ΔGSolv2
ΔG’Solv2
ΔG2
α-Indomethacin γ-Indomethacin
ΔGSolv3 ΔG’Solv3
ΔG3
α-Indomethacin γ-Indomethacin
Diagram 1: Thermodynamic cycle of solvation Gibbs free energies.
As seen from Diagram 1, the spontaneity of a transformation depends on the difference between
the Gibbs free energies of the polymorphs, which can be clarified here with the aid of Figure 7. The
solvation Gibbs free energies
γ
SolvG and αSolvG are directly related to the difference between the
Gibbs free energy of transformation into different solvents and in the vacuum, as established by the
following equation [33]:
(7)
Next, indomethacin treated in different solvents shows diverse values of ΔG as a result of the medium
permittivity, which provides a particular equilibrium constant K for each solvent, as schematized in
the following equation [33]:


 
RT
ΔG(ε
=
α
γ
=K
RT
εΔG
=K
)
exp
][
][
      
)(
ln
(8)
)GG(+G=G αSolv
γ
Solvvac 
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where [α] and [γ] denote the molarity of α- and γ-indomethacin, respectively. Then, the sign of ΔG
determines which polymorph is the most abundant and its proportion. The molarity of γ-indomethacin
is greater than that of α-indomethacin if ΔG < 0. Therefore, α-indomethacin can be more abundant
than γ-indomethacin in solvents with negative permittivity values. In terms of bioavailability, Figure 3
shows that the molar ratio [α]/[γ] is higher for positive permittivity values, which in turn are close to
the vacuum permittivity. The solvation energies can also be assigned as a function of permittivity, as
follows.
Figure 5: Solvation Gibbs free energy versus relative permittivity.
The solvation Gibbs free energy data plotted in Figure 5 provides the parameters from the nonlinear
fitting depicted in Table 3.
Table 3: Parameters from the nonlinear fitting of the solvation Gibbs free energy
Equation Gsolv= a+b/(ε-c)
Plot Solvation Gibbs free energy
ɑ-indomethacin
Solvation Gibbs free energy
γ-indomethacin
a -237.9101 1.003 -286.89872122.225
13
b 518.572881333.83 547.467981374.29
c -1.5525130.3831 -1.439130.78462
Reduced Chi-Sqr 0.78542 3.94291
R-Square(COD) 0.99895 0.99547
Adj. R-Square 0.9986 0.99396
Therefore, Table 3 provides the parameters used to express the Gibbs free energies of solvation:
Gsolv,ɑ= -237.91016 + 518.57288/(ε+1.5525) (9)
Gsolv,γ= -286.89872 + 547.46798/(ε+1.439) (10)
The current analysis allows the generalization of the Born equation, as shown in equation (11)
[46,33].
ΔGSolv= β(-1+1/ε) (11)
where β is an experimental constant [31]. The enthalpy, Gibbs free energy and solvation heat can be
generalized as follows [33]:
P=Pi+c(ε-εi)-1 (12)
where Pi, εi and c are the experimental constants. The behavior of the thermodynamic function P near
a phase transition is characterized by the critical exponent -1. Hence, P can be expanded around the
value ε=0, and for very large ε, it is given by the following:
P=Pi+c[-(1/εi)-(ε/εi2)-(ε2/εi3)+O(ε3)] (13a)
P=Pi+c[(1/ε)+(εi/ε2)+(εi2/ε3)+O(ε4)] (13b)
Equations (12) and (13) were derived from ab initio and first-order computations of a thermodynamic
function involving an electric field D medium, in which a term due to the electric energy stored in the
dielectric medium of the solvent is incorporated into the thermodynamic structure. The Gibbs free
energy is shown by the following:
G = U - TS + PV = μN + D2/8πε (14)
14
Other thermodynamic functions thus come similarly [11].
CONCLUSIONS
The present study focuses on the thermodynamic behavior of polymorphic phase transitions
between the α and γ phases of indomethacin induced by different polar solvents and in terms of their
permittivity. Hence, the enthalpy, Gibbs free energy, entropy and solvation Gibbs free energy were
computed at 298.15 K in a nucleation process for various permittivity values of the solvents.
The validation of the DFT method was established by matching the α and γ critical transition
temperature at the standard value of 807.45 K, followed by the systematic study of the main direction
of the polymorphic transformation, α→γ or γ →α, by the variation of the permittivity. The main
results provide insights regarding the mechanisms of drug bioavailability and are summarized as
follows:
 The enthalpy shows exothermic transformations from α- to γ-indomethacin for each positive
value of the permittivity. However, for some negative values of permittivity, characterized by
metamaterials [36], the transformation from α to γ is endothermic;
 The Gibbs free energy analysis guarantees the spontaneous transformation from α- to
γ-indomethacin and, consequently, a higher concentration of γ-indomethacin for all positive
permittivity values. However, for values of ε close to vacuum permittivity, indomethacin presents
the highest concentration of α-indomethacin among the positive permittivity values. Moreover,
for negative permittivity [37], γ- indomethacin spontaneously transforms into α-indomethacin;
 Due to the discontinuity (∂S/∂ε)|ε- ≠ (∂S/∂ε)|ε+, wherein the subscript signs - and + indicate the left
and right limits of ε, respectively, there is a first-order phase transition of the entropy at ε = 11.46.
For ε < 11.46, the γ-indomethacin phase is more disordered; otherwise, α-indomethacin is more
disordered when ε > 11.46.
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